Stifel reiterates Onto Innovation stock rating ahead of earnings By Investing.com

Stifel reiterated a Buy on Onto Innovation with a $350 price target ahead of earnings, implying meaningful upside from the current $292.92 share price. The company has pre-announced stronger Q1 results, raised Q2 guidance, and expects second-half revenue to rise in the low double digits sequentially and 40% to 50% year over year. Analyst sentiment remains constructive, supported by Dragonfly G5 qualifications, advanced packaging momentum, and the $710 million acquisition of a 27% stake in Rigaku.

Analysis

ONTO is increasingly a second-derivative AI/advanced-packaging winner, but the bigger implication is that its product mix is shifting from “good tools company” to a levered exposure on customer capex cycles at the most constrained parts of the semiconductor stack. If Dragonfly G5 is now qualified into 2.5D flows, the marginal buyer is not just a single fab but the broader heterogeneous integration ecosystem, which should improve durability of orders even if leading-edge wafer starts wobble. That said, the stock’s multiple already discounts a lot of this re-acceleration, so the market will likely punish any hint of timing slippage more than it rewards incremental upside.

The most interesting second-order effect is competitive: ONTO’s strengthening position in packaging and process control can pressure smaller metrology vendors that lack adjacent X-ray or packaging exposure, while also increasing strategic value to foundry/IDM customers seeking fewer point-solution suppliers. For TSM, the relevance is operational rather than financial; any broad adoption of advanced packaging inspection tools supports capacity utilization and yield improvement, but it also reinforces TSM’s dependence on a handful of specialized equipment ecosystems that can become bottlenecks if qualification ramps lag. Over the next 3-6 months, the key variable is not demand, it’s shipment cadence and whether customers convert qualifications into volume deployments fast enough to justify current sell-side enthusiasm.

Consensus appears to be underestimating how much of the near-term upside is already embedded after the pre-announcement and target raises. The cleaner trade is not chasing the common-stock upside into earnings, but structuring around the binary: if management confirms a steep second-half inflection and packaging ramps, the stock can rerate into the high-300s; if guidance is merely reiterated, valuation compression can be sharp because the setup is crowded and expectations are elevated. The biggest contrarian risk is that this becomes a “great company, fully owned stock,” where execution is solid but not enough to beat a narrative that has run ahead of the actual backlog conversion rate.

Key Decisions for Investors

• Avoid adding ONTO common into earnings; use a defined-risk call spread instead: buy the Jul/Aug upside spread if implied vol is still below the post-announcement realized range, targeting a 1.5x-2.0x payoff if management confirms 2H acceleration.
• If already long ONTO, hedge with short-dated downside puts or a collar into the print; the risk/reward skews to a 10-15% drawdown on merely in-line guidance versus limited incremental upside if numbers are just “good.”
• Pair trade: long ONTO / short a slower-growth process-control peer on any post-earnings strength, betting that packaging exposure and second-half acceleration drive relative outperformance over the next 1-3 months.
• Use TSM as a lower-beta proxy for advanced packaging capex only on pullbacks; the cleaner catalyst is ecosystem capex confirmation over the next 2 quarters, not the event itself.
• If ONTO gaps up >8% on earnings, take partial profits into strength and wait for a retracement before reloading; this name is likely to trade on guidance quality, not just a beat.